Esophageal adenocarcinoma

Reflux-promoting drugs may raise risk for esophageal adenocarcinoma.

August 3, 2000

NEW YORK, August 2 (Praxis Press) An increase in the incidence of esophageal adenocarcinoma was first reported in the 1970s, a time period during which drugs that relax the lower esophageal sphincter (LES) had gained widespread use. Lagergren and colleagues studied the association of upper gastrointestinal tract cancers and use of several classes of LES-relaxing drugs. The study included 189 subjects with esophageal adenocarcinoma, 262 with adenocarcinoma of the gastric cardia, 167 with esophageal squamous cell carcinoma, and 820 control subjects. When compared with patients who had never used LES-relaxing drugs, patients who used them daily for more than five years had an estimated incidence rate ratio of 3.8 for esophageal adenocarcinoma; this association was strongest for anticholinergic drugs. In contrast, no association was noted for adenocarcinoma of the gastric cardia or esophageal squamous cell carcinoma. The therapeutic benefits of LES-relaxing drugs may be slightly offset by an increased risk of esophageal adenocarcinoma.

Popular Now

  1. National Academies Detail the State of Weed Science
  2. Neural Mechanism Links Alcohol Consumption to Binge Eating
  3. Image of the Day: Monkey Business
    Image of the Day Image of the Day: Monkey Business

    For the first time, researchers have documented interspecies sexual behavior between a male Japanese macaque and a female sika deer.

  4. Trumping Science: Part III
    The Nutshell Trumping Science: Part III

    Scientists criticize unconfirmed reports that President-elect Donald Trump has asked Robert Kennedy Jr., an anti-vaccine activist, to investigate vaccine safety.

RayBiotech